of newly registered patients at 2 outpatient facilities in Amsterdam (The Netherlands) of age 18-65 years with a DSM-IV-defined major depressive disorder of mild to moderate severity. SPSP involves an open patient-therapist dialogue that uses supportive and insight-facilitating techniques to address the emotional background of depression and was delivered in 16 sessions of 45 min within a 24-week period. In the combined condition, antidepressants were provided for 24 weeks according to a protocol with several steps in case of intolerance or inefficacy: first venlafaxine, followed by fluoxetine, and finally nortriptyline. Sixteen depressive symptoms were assessed at baseline and after 24 weeks with the depression subscale of the Symptom Checklist-90. Analyses were conducted in a sample consisting of all patients who started with the treatment they were allotted to (psychotherapy, n = 103; combined therapy, n = 83; see the online suppl. material for the sample characteristics; for all online suppl. material, see www.karger.com/doi/10.1159/000486793) and the last outcome carried forward method was applied. First, we focused on the relative efficacy of psychotherapy versus combined therapy by using individual symptoms as effect parameters and, then, differentiated between direct and indirect effects by taking into account symptom interrelatedness in a network model.
Symptom-specific efficacy of psychotherapy versus combined therapy was investigated using independent sample t tests with change scores (post-minus pre-treatment) of depressive symptoms as dependent variables. Combined therapy was significantly more effective than psychotherapy in decreasing the symptoms feeling entrapped ( symptoms showed similar responses to psychotherapy and combined therapy (Fig. 1) .
Then, we took into account symptom interrelatedness to differentiate between the direct and indirect effects of the addition of pharmacotherapy to psychotherapy. An L1-regularized partial correlation network of treatment type and change scores of all depressive symptoms was estimated (the network estimation procedure and tests for parameter estimate accuracy are described in the online suppl. material). Figure 1 shows that changes in depressive symptoms during treatment were strongly related. The strongest association was found between thoughts of death and thoughts of suicide (partial correlation = 0.49), indicating that persons with an improvement in thoughts of death during treatment were more likely to experience an improvement in thoughts of suicide as well. Treatment type showed the strongest direct connections to feeling entrapped (partial correlation = 0.16) and emotional lability (partial correlation = 0.11), and was weakly connected to worry (partial correlation = 0.04), low in energy (partial correlation = 0.01), and hopelessness (partial correlation = 0.01). All connections were in A number of studies have reported that adding pharmacotherapy to psychotherapy has no or only small advantages in the treatment of mild to moderate depression [1] [2] [3] . These studies have used sum scores of depression rating scales as effect parameters [1] [2] [3] . However, as individual items on these scales have recently been shown to respond differentially to pharmacotherapy compared to placebo [4] , the effects of an addition of pharmacotherapy to psychotherapy may only be detectable by focusing on individual depressive symptoms.
Previous studies investigating treatment responses of individual depressive symptoms (e.g., Hieronymus et al. [4] ) did not take into account the potential interrelatedness of these symptoms. For example, patients who become less self-blaming in response to treatment may also be more likely to experience reductions in feelings of worthlessness or blue mood. Tools to consider symptom interrelatedness are offered by the network approach, which conceptualizes depression as a system of associated symptoms [5] . Earlier network studies have demonstrated that depressive symptoms are differentially related to one another [5] [6] [7] ; however, it remains unknown if similar association patterns exist among changes in these symptoms during treatment. Taking into account these relations in a network structure provides the opportunity to determine the effects of adjunctive pharmacotherapy on specific symptoms while adjusting for responses of other symptoms. This enables a differentiation between direct symptom-specific effects (i.e., those independent of changes in other symptoms) and indirect symptom-specific effects (i.e., those mediated by changes in other symptoms).
This is the first study to determine the relative efficacy of psychotherapy versus combined therapy on individual depressive symptoms. Data were derived from a randomized controlled trial comparing short-term psychodynamic supportive psychotherapy (SPSP) and this therapy combined with pharmacotherapy in patients with mild to moderate depression [1] . Participants consisted favor of combined therapy, suggesting that this therapy targeted these particular symptoms directly.
Despite their significant responses to the addition of pharmacotherapy to psychotherapy in our first analysis, obsessive thoughts and blue mood were not directly connected to treatment type in the network, and worry, low in energy, and hopelessness showed only weak direct associations to this variable. Interestingly, the network revealed that these symptoms were related to changes in feeling entrapped and emotional lability, which in turn were more strongly connected to the type of treatment. This suggests that the effect of adjunctive pharmacotherapy on obsessive thoughts, blue mood, worry, low in energy, and hopelessness may largely have been indirect and could have been mediated by changes in feeling entrapped and emotional lability.
A strength of this study is that the trial included a fairly random and representative sample of mildly to moderately depressed patients in secondary care. Furthermore, we estimated the network structure using l1-regularization to prevent overfitting, which has been shown to adequately control for false positive associations. However, in our relatively small sample of 186 individuals, small true positive associations could have been overlooked [8] . As baseline scores in our sample differed across symptoms, it is also important to note that a higher baseline severity of symptoms was associated with stronger responses to adjunctive pharmacotherapy, which is in line with previous reports [2] .
In conclusion, this study showed that combined therapy outperformed psychotherapy in the treatment of some depressive symptoms and not others. Although our results are exploratory rather than conclusive, they suggest that adjunctive pharmacotherapy targeted specific symptoms (e.g., feeling entrapped, emotional lability) directly and other symptoms (e.g., obsessive thoughts, blue mood) indirectly. As direct effects are independent of changes in other symptoms, our findings imply that adjunctive pharmacotherapy can effectuate improvements in directly targeted symptoms in all patients irrespective of changes in other symptoms. Indirectly targeted symptoms, in contrast, may respond to an addition of pharmacotherapy to psychotherapy, but only in patients improving on symptoms mediating these responses during treatment and, therefore, reporting these symptoms before treatment. If replicated, these insights may help clinicians to predict which patients could benefit from an addition of pharmacotherapy to psychotherapy [9] .
Given the differential treatment responses across symptoms, we would like to encourage other researchers to analyze individual depressive symptoms as well as their interrelatedness. Network models are highly promising in this approach as they can be expanded with other psychiatric or physical symptoms (e.g., anxiety, nausea) to provide insight into secondary or side effects of a treatment independent of its effects on depressive symptoms. Furthermore, dynamic networks of depressive symptoms during various treatment stages could reveal that changes in specific symptoms are preceded by changes in other symptoms, which may inform on pathways underlying indirect responses of symptoms to a treatment [10] .
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